| PROTAC | Proteolysis-Targeting Chimera |
| UPS | Ubiquitin–Proteasome System |
| E3 | E3 Ubiquitin Ligase |
| CRBN | Cereblon |
| VHL | Von Hippel–Lindau Protein |
| MDM2 | Mouse Double Minute 2 Homolog |
| LYTAC | Lysosome-Targeting Chimera |
| RNA | Ribonucleic Acid |
| DNA | Deoxyribonucleic Acid |
| TCGA | The Cancer Genome Atlas |
| PPIs | Protein–Protein Interactions |
| AI | Artificial Intelligence |
| PK/PD | Pharmacokinetics/Pharmacodynamics |
| CNS | Central Nervous System |
| TPD | Targeted Protein Degradation |
| FDA | Food and Drug Administration |
| IND | Investigational New Drug |
| SAR | Structure–Activity Relationship |
| SPR | Surface Plasmon Resonance |
| ADME | Absorption, Distribution, Metabolism, and Excretion |
| KEAP1 | Kelch-like ECH-associated Protein 1 |
| DCAF16 | DDB1- and CUL4-Associated Factor 16 |
| UHRF1 | Ubiquitin-like with PHD and RING Finger Domains 1 |
| SCF | Skp1–Cullin–F-box Complex |
| DUB | Deubiquitinating Enzyme |
| BRD4 | Bromodomain-Containing Protein 4 |
| BCL-xL | B-Cell Lymphoma-Extra Large |
| CDK | Cyclin-Dependent Kinase |
| KRAS | Kirsten Rat Sarcoma Viral Oncogene |
| EGFR | Epidermal Growth Factor Receptor |